Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
Schernthaner G
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00059-0.
Leggi
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
Khunti K, Knighton P, Zaccardi F, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00050-4.
Leggi
Glycemic index, glycemic load, and cardiovascular disease and mortality
Jenkins DJA, Dehghan M, Mente A, et al.
N Engl J Med. 2021;384:1312-1322
Leggi
PROGETTO INERZIA – Monografia Inerzia Clinica
Carissimi Soci, nell’ambito del progetto “L’inerzia clinica nel diabete di tipo 2: valutazione della multifattorialità del problema ed impatto dell’emergenza coronavirus”, siamo lieti di comunicarvi che è disponibile sul sito Annali AMD la pubblicazione della nuova monografia Annali “Indicatori di inerzia clinica nel DM2”. Alla luce delle nuove raccomandazioni ESC/EASD, è emerso…
Leggi
Improved glycemic outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes
Collyns OJ, Meier RA, Betts ZL, et al.
Diabetes Care. 2021;44(4):969-975.
Leggi
Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial
Weissler EH, Clare RM, Lokhnygina Y, et al.
Diabet Med. 2021;e14552
Leggi
The impact of guideline integration into electronic medical records on outcomes for patients with diabetes: a systematic review
Shah S, Yeheskel A, Hossain A, et al.
Am J Med. Pub. online 25 March 2021
Leggi
(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen B, Metzendorf MI, Richter B
Cochrane Database Syst Rev. 2021;3:CD013498
Leggi
Not all patients with “type 2” diabetes are equal
Yoel Toledano, Hilla Knobler
Am J Med. 2021;S0002-9343(21)00154-6
Leggi